bioRxivImmunologyPreprint
Potent Neutralization by Antibodies Targeting the Mpox A28 Protein
Ron YefetiD, Leandro BattiniiD, Mathieu HubertiD, Katya Rakayev, Florence Guivel‐BenhassineiD, Noam RattneriD, Françoise PorrotiD, Lilach AbramovitziD, Gilad Ostashinsky, Noam Ben-ShalomiD, Jeanne PostaliD, Ksenia PolonskyiD, Maya Ralph-Altman, Sireen Sweed, T. W. Körner, Nadav Friedel, David HaginiD, Eli SprecheriD, Zvi FishelsoniD, Oren KobileriD, Lihi Adler‐AbramovichiD, Olivier SchwartziD, Pablo Guardado‐CalvoiD, Natalia Tarnovitski FreundiD
Abstract
Mpox is the most pathogenic Poxvirus in circulation. While several antigens have been identified as targets for neutralizing antibodies, many proteins remain unexplored. We isolated and characterized four monoclonal antibodies (mAbs) targeting the Mpox A28 (OPG153), a virulence factor present on mature Mpox virions. The antibodies were isolated from convalescent individuals, alongside 14 additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralized Mpox and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High resolution crystal structures of Anti-A28 mAbs 10M2146 and 8M2110 in complex with VACV A26 revealed two proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 attenuated disease in infected mice. Moreover, immunization with A28 elicited antigen-specific B cells and robust neutralizing antibody responses and provided complete protection against lethal VACV challenge. These findings support Mpox A28 as a promising target for the induction of neutralizing antibodies and antiviral interventions.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: wet-lab / biochemical assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153
Ida Paciello, Ling Zhou, … Emanuele Andreano·Science Translational MedicinePeer-reviewed·Dec 10, 2025
- Comprehensive Profiling of Monkeypox Virus Antigens Identifies Potent Targets for Next-Generation mRNA Vaccine Development
Alexandra C. Walls, Harman Malhi, … Adam Zuiani·bioRxiv·Jun 24, 2026
- A human-derived two-antibody cocktail confers prophylactic and therapeutic protection against authentic Mpox virus.
Birte Kalveram, Awadalkareem Adam, … Hugues Fausther‐Bovendo·bioRxiv·Sep 1, 2026
- A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge
A. W. Freyn, C. Atyeo, … B. Moss·bioRxiv·Dec 17, 2022
- A Quadrivalent mRNA immunization elicits potent immune responses against vaccinia and monkeypox viral antigens - a step closer to a broad orthopoxvirus vaccine
- Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus